Here are the 424B prospectus supplements from ABIVAX SA (AAVXF) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow AAVXF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AAVXF filings page.
Abivax SA is conducting a public offering of 6,400,000 ADSs at $125.00 per ADS. The offering price implies gross proceeds of $800,000,000 before underwriting discounts; proceeds to the company before expenses are $762,000,000. The underwriters have a 30-day option to purchase up to 960,000 additional ADSs.
The company recently repurchased royalty certificates for aggregate consideration of $90.0 million, funded half in cash and half by issuing 403,347 ordinary shares (including ADSs). Abivax reported positive topline Phase 3 maintenance results for obefazimod in ulcerative colitis, with higher response and remission rates at the 50 mg dose in exploratory cohorts and safety findings summarized across treatment arms.
Abivax SA is offering up to $600,000,000 of American Depositary Shares (ADSs), each representing one ordinary share. The ADSs trade on Nasdaq under the symbol ABVX and the ordinary shares trade on Euronext Paris under ABVX. The prospectus supplement describes offering mechanics, underwriting arrangements and customary lock-ups, and registers resale of ADSs issued in a prior private placement in connection with a $90.0 million royalty certificate repurchase (403,347 ADSs issued).
The supplement also discloses positive topline results from Part 2 of the Phase 3 ABTECT 44‑week maintenance trial for obefazimod, including Week 44 clinical remission of 37.2% for the 50 mg arm (induction non-responders) and safety tables summarizing treatment-emergent adverse events and malignancy incidence metrics used for exposure‑adjusted comparisons.